Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone: bluebeard for malignancies.

W T van der Graaf1, E G de Vries

  • 1Department of Internal Medicine, University Hospital, Groningen, The Netherlands.

Anti-Cancer Drugs
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interpersonal differences in the friction response of skin relate to FTIR measures for skin lipids and hydration.

Colloids and surfaces. B, Biointerfaces·2020
Same author

Friction in the contact between skin and a soft counter material: Effects of hardness and surface finish.

Journal of the mechanical behavior of biomedical materials·2019
Same author

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.

European journal of cancer (Oxford, England : 1990)·2018
Same author

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018
Same author

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same journal

Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen.

Anti-cancer drugs·2026
Same journal

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Anti-cancer drugs·2026
Same journal

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.

Anti-cancer drugs·2026
Same journal

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Anti-cancer drugs·2026
Same journal

Drug repurposing of liver cancer based on multimodal neural network and virtual screening.

Anti-cancer drugs·2026
Same journal

Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.

Anti-cancer drugs·2026
See all related articles

Mitoxantrone is an effective chemotherapy drug for breast cancer, leukemia, and lymphoma. It offers improved tolerability over doxorubicin but requires monitoring for myelotoxicity, mucositis, and cardiotoxicity, especially at higher cumulative doses.

Area of Science:

  • Pharmacology and Toxicology
  • Medical Oncology

Background:

  • Mitoxantrone, an anthracenedione derivative, has been utilized in research and clinical settings since the late 1970s.
  • Proposed mechanisms of action include DNA intercalation and electrostatic interactions, potentially involving topoisomerase II, alongside immunosuppressive effects and prostacyclin synthesis inhibition.

Purpose of the Study:

  • To review the efficacy, mechanisms, and safety profile of mitoxantrone in cancer therapy.
  • To compare mitoxantrone's tolerability and toxicity with doxorubicin.

Main Methods:

  • Review of preclinical and clinical studies on mitoxantrone.
  • Analysis of proposed working mechanisms and therapeutic applications.
  • Evaluation of safety data, including dose-limiting toxicities and cardiotoxicity.

Related Experiment Videos

Main Results:

  • Mitoxantrone demonstrates efficacy in breast cancer, leukemia, and lymphoma, both as a monotherapy and in combination regimens.
  • It is suitable for locoregional therapy due to being a non-vesicant, offering improved tolerability compared to doxorubicin.
  • Primary toxicities are myelotoxicity and mucositis; cardiotoxicity is less frequent than with anthracyclines but warrants monitoring.

Conclusions:

  • Mitoxantrone is a valuable chemotherapeutic agent with a manageable safety profile, particularly beneficial in specific cancer types.
  • High-dose regimens with supportive care and careful monitoring for cumulative dose-related toxicities are crucial for optimal patient outcomes.